We confirmed that the effects of miRisten was indeed due to reduction of miR-126 since miRisten treatment in inv(16) AML CD34+ cells showed no additional effect when miR-126 was knocked down with shmiR-126 (Supplementary Fig. 9h, i). The gene discussed is CD34; the disease is acute myeloid leukemia.